The Effects of Ketamine and Esketamine on Measures of Quality of Life in Major Depressive Disorder and Treatment-Resistant Depression: A Systematic Review

This publication has 20 references indexed in Scilit:

• Glutamatergic Modulators for Major Depression from Theory to Clinical Use
  CNS Drugs, 2024
• Safety and tolerability of esketamine nasal spray versus quetiapine extended release in patients with treatment resistant depression
  European Neuropsychopharmacology, 2024
• Long-term quality of life after repeated ketamine infusions in anxious and nonanxious patients with depression
  Journal of Affective Disorders, 2024
• Dextromethorphan-Bupropion for the Treatment of Depression: A Systematic Review of Efficacy and Safety in Clinical Trials
  CNS Drugs, 2023
• Treatment‐resistant depression: definition, prevalence, detection, management, and investigational interventions
  World Psychiatry, 2023
• Effects of esketamine on patient-reported outcomes in major depressive disorder with active suicidal ideation and intent: a pooled analysis of two randomized phase 3 trials (ASPIRE I and ASPIRE II)
  Quality of Life Research, 2023
• Efficacy of ketamine and esketamine on functional outcomes in treatment-resistant depression: A systematic review
  Journal of Affective Disorders, 2021
• Burden of Treatment Resistant Depression (TRD) in patients with major depressive disorder in Ontario using Institute for Clinical Evaluative Sciences (ICES) databases: Economic burden and healthcare resource utilization
  Journal of Affective Disorders, 2020
• Validity and Reliability of the Assessment of Quality of Life (AQoL)-8D Multi-Attribute Utility Instrument
  The Patient - Patient-Centered Outcomes Research, 2013
• Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)
  Quality of Life Research, 2011